Saar I Gill, MD, PhD

faculty photo
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending, Hospital of the University of Pennsylvania
Member, Institute for Immunology
Member, Abramson Cancer Center
Scientific Co-Director, University of Pennsylvania Cell Therapy and Transplant group
Department: Medicine

Contact information
Room 8-101
Smilow Translational Research Center
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 573-4015
Lab: (215) 573-4015
MBBS (medicine)
University of Melbourne, 1999.
PhD (immunology)
University of Melbourne, 2011.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Blood and Marrow Transplantation
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
Lymphoproliferative Neoplasms
Bone Marrow Failure

Description of Research Expertise

Tumor Immunology
Chimeric Antigen Receptor T cells
Mouse Models of Human Leukemia
Murine Xenografts
Adoptive Cellular Therapy
Genetic Engineering of T cells
Flow Cytometry

Selected Publications

Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV.: Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Transplant Cell Ther 2023.

Christopher Snyder & Saar Gill: Good CARMA: Turning bad tumor-resident myeloid cells good with chimeric antigen receptor macrophages. Immunol Rev. 2023.

Rohtesh S Mehta 1 , Haris Ali 2 , Yang Dai 3 , Bert Yao 3 , Bethany Overman 4 , Voravit Ratanatharathorn 5 , Saar Gill 6 , Gerard SociƩ 7 , Kevin Anderson 3 , Jean Yves Cahn 8 , Arshad Mujeebuddin 3 , Richard Champlin 4 , Elizabeth Shpall 4 , Shernan G Holtan 9 , Amin Alousi: A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplant 2023.

Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. 2023.

Katherine Cummins & Saar Gill: Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Hematol Oncol Clin North Am. 2023.

Welty NE, Gill SI.: Cancer Immunotherapy Beyond Checkpoint Blockade: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 4: 563-578, Dec 2022.

Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, Ballard HJ, Hong SJ, Chun I, Yang N, Amelsberg KV, Cummins KD, Svoboda J, Gill S, Chong EA, North K, Church SE, Fraietta JA, Chang WJ, Lacey SF, Lu XM, Zhang Y, Whig K, Schultz DC, Cherry S, Gerson J, Schuster SJ, Porazzi P, Ruella M.: Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer. Cancer Discov 12: 2372-2391, Oct 2022.

Sharma A, Farnia S, Otegbeye F, Rinkle A, Shah J, Shah NN, Gill S, Maus MV.: Nomenclature for Cellular and Genetic Therapies: A Need for Standardization. Transplant Cell Ther Sep 2022.

Diorio C, Shraim R, Myers R, Behrens EM, Canna S, Bassiri H, Aplenc R, Burudpakdee C, Chen F, DiNofia AM, Gill S, Gonzalez V, Lambert MP, Leahy AB, Levine BL, Lindell RB, Maude SL, Melenhorst JJ, Newman H, Perazzelli J, Seif AE, Lacey SF, June CH, Barrett DM, Grupp SA, Teachey DT.: Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clin Cancer Res 28: 3804-3813, Sep 2022.

Saygin C, Roloff GW, Hahn CN, Chhetri R, Gill SI, Elmariah H, Talati C, Nunley E, Gao G, Kim A, Bishop MR, Kosuri S, Das S, Singhal D, Venugopal P, Homan CC, Brown AL, Scott HS, Hiwase DK, Godley LA.: Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv 7: 549-554, Aug 2022.

back to top
Last updated: 08/21/2023
The Trustees of the University of Pennsylvania